Stock listing
Jw (cayman) Therapeutics Co. Ltd.
Selected listing: A2QFV3 · LSX · EUR · DE
Jw (cayman) Therapeutics Co. Ltd. (LS Exchange: A2QFV3), Health Technology. Latest release Oct 31, 2025: JW Therapeutics and Regeneron Expand Strategic…
- Ticker
- LS Exchange: A2QFV3
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
Latest news from Jw (cayman) Therapeutics Co. Ltd.
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
October 31, 2025
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
June 3, 2025
JW Therapeutics - Receipt of Breakthrough Therapy Designation for Carteyva in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
January 13, 2025
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
July 4, 2022
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
March 31, 2022
Research Jw (cayman) Therapeutics Co. Ltd.
Jw (cayman) Therapeutics Co. Ltd. company profile
View the public company page for Jw (cayman) Therapeutics Co. Ltd. on 6ix.
Jw (cayman) Therapeutics Co. Ltd. news
Read company news and market updates connected to Jw (cayman) Therapeutics Co. Ltd..
Jw (cayman) Therapeutics Co. Ltd. investor events
Find investor webinars, events, and replay context for Jw (cayman) Therapeutics Co. Ltd..
Alternate listings
2126:HKEX
HK · HKD
Alternate listing for Jw (cayman) Therapeutics Co. Ltd.; the primary context on this page is A2QFV3:LSX.
JNY:FWB
DE · EUR
Alternate listing for Jw (cayman) Therapeutics Co. Ltd.; the primary context on this page is A2QFV3:LSX.
A2QFV3:LS
DE · EUR
Alternate listing for Jw (cayman) Therapeutics Co. Ltd.; the primary context on this page is A2QFV3:LSX.
JWCTF:OTC
US · USD
Alternate listing for Jw (cayman) Therapeutics Co. Ltd.; the primary context on this page is A2QFV3:LSX.